Contact
Please use this form to send email to PR contact of this press release:
Human medicines European public assessment report (EPAR): Reblozyl, luspatercept, Anemia;Myelodysplastic Syndromes;beta-Thalassemia, Date of authorisation: 25/06/2020, Revision: 5, Status: Authorised
TO: